Author:
Menges Dominik,Piatti Michela C.,Omlin Aurelius,Cathomas Richard,Benamran Daniel,Fischer Stefanie,Iselin Christophe,Küng Marc,Lorch Anja,Prause Lukas,Rothermundt Christian,O'Meara Stern Alix,Zihler Deborah,Lippuner Max,Braun Julia,Cerny Thomas,Puhan Milo A.
Funder
Swiss Cancer Research Foundation
Béatrice Ederer-Weber Stiftung
Swiss Cancer Foundation
Reference55 articles.
1. European Medicines Agency. The patient’s voice in the evaluation of medicines. London, UK: EMA; 2013. https://www.ema.europa.eu/en/documents/report/report-workshop-patients-voice-evaluation-medicines_en.pdf.
2. Medical Device Innovation Consortium. Patient centered benefit‐risk project report: a framework for incorporating information on patient preferences regarding benefit and risk into regulatory assessments of new medical technology. Silver Spring, MD: FDA; 2015. https://www.fda.gov/media/95591/download.
3. US Food and Drug Administration. Patient-focused drug development guidance series for enhancing the incorporation of the patient’s voice in medical product development and regulatory decision making. Silver Spring, MD: FDA; 2020. https://www.fda.gov/drugs/development-approval-process-drugs/fda-patient-focused-drug-development-guidance-series-enhancing-incorporation-patients-voice-medical.
4. A framework for incorporating patient preferences regarding benefits and risks into regulatory assessment of medical technologies;Ho;Value Health,2016
5. Patient-focused benefit-risk analysis to inform regulatory decisions: the European Union perspective;Mühlbacher;Value Health,2016